EC readies deal with biotech company Valneva for new potential vaccine

The substance is currently the only one in clinical trials against Covid-19 in Europe made under traditional technology

The Commission envisages contract with a European biotechnology company Valneva, developer of an inactivated virus vaccine under a traditional technology. On Tuesday, the EU executive concluded exploratory talks with this pharmaceutical producer with a view to purchasing its potential vaccine against Covid-19. 

The used technology would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses.

The finalisation of exploratory talks with Valneva come in addition to an already secured broad portfolio of vaccines to be produced in Europe, including the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, and Moderna and exploratory talks concluded with Novavax.

This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective, as is already the case for BioNTech/Pfizer and Moderna, recently authorised in the EU.

Valneva’s substance is currently the only inactivated vaccine candidate in clinical trials against Covid-19 in Europe.

EU countries will have the possibility to donate vaccines to lower and middle-income countries or to re-direct it to other states in Europe.

The continuing Covid-19 pandemic in Europe and around the globe makes it more important than ever that all Member States have access to the broadest possible portfolio of vaccines to help protect people in Europe and beyond, EC President Ursula von der Leyen commented.  

According to Stella Kyriakides, Commissioner for Health and Food Safety, with this eighth vaccine, the EU is adding to its already broad and diversified range of vaccines in our portfolio. By doing this, we can maximise our chances of making sure that all citizens can have access to safe and effective of vaccinations by the end of 2021, she also said adding that all Member States will start receiving an increasing number of doses in order to cover all their needs during this year.

 

Similar articles